Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

[1]  S. Arnold,et al.  Cardiovascular Outcomes and Mortality in Type 2 Diabetes with Associated Cardio-Renal-Metabolic Comorbidities , 2018, Diabetes.

[2]  C. Antoniades,et al.  Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets , 2017, British journal of pharmacology.

[3]  T. Wakatsuki,et al.  Echocardiographic Epicardial Adipose Tissue Thickness Is Associated with Symptomatic Coronary Vasospasm during Provocative Testing , 2017, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[4]  T. Yoshimoto,et al.  Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study , 2017, Diabetes Therapy.

[5]  S. Takanashi,et al.  Gender-linked impact of epicardial adipose tissue volume in patients who underwent coronary artery bypass graft surgery or non-coronary valve surgery , 2017, PloS one.

[6]  Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials , 2017, BMC Pharmacology and Toxicology.

[7]  T. Yoshimoto,et al.  Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study , 2017, Cardiovascular Diabetology.

[8]  Sung Hee Choi,et al.  Comparison between two methods of bioelectrical impedance analyses for accuracy in measuring abdominal visceral fat area. , 2016, Journal of diabetes and its complications.

[9]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[10]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[11]  T. Wakatsuki,et al.  Clinical Utility of Measuring Epicardial Adipose Tissue Thickness with Echocardiography Using a High-Frequency Linear Probe in Patients with Coronary Artery Disease. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[12]  S. Rabkin,et al.  Comparison of reducing epicardial fat by exercise, diet or bariatric surgery weight loss strategies: a systematic review and meta‐analysis , 2015, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[13]  M. Davies,et al.  Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus , 2015, Diabetes, obesity & metabolism.

[14]  Raimund Erbel,et al.  Association of epicardial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis: results from the Heinz Nixdorf recall study. , 2014, JACC. Cardiovascular imaging.

[15]  T. Nakanishi,et al.  SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria , 2014, Biopharmaceutics & drug disposition.

[16]  I. Kubota,et al.  Increased epicardial adipose tissue volume predicts insulin resistance and coronary artery disease in non-obese subjects without metabolic syndrome , 2014 .

[17]  K. Chou,et al.  The relation of location-specific epicardial adipose tissue thickness and obstructive coronary artery disease: systemic review and meta-analysis of observational studies , 2014, BMC Cardiovascular Disorders.

[18]  K. Aihara,et al.  Association of lower limb muscle mass and energy expenditure with visceral fat mass in healthy men , 2014, Diabetology & Metabolic Syndrome.

[19]  R. DeFronzo,et al.  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.

[20]  Lawrence A Leiter,et al.  Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial , 2013, The Lancet.

[21]  MichioShimabukuro,et al.  Epicardial Adipose Tissue Volume and Adipocytokine Imbalance Are Strongly Linked to Human Coronary Atherosclerosis , 2013 .

[22]  G. Kimura,et al.  Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study , 2012, European journal of clinical investigation.

[23]  T. Wakatsuki,et al.  Gender disparities in the association between epicardial adipose tissue volume and coronary atherosclerosis: A 3-dimensional cardiac computed tomography imaging study in Japanese subjects , 2012, Cardiovascular Diabetology.

[24]  I. Seong,et al.  Effects of Statins on the Epicardial Fat Thickness in Patients with Coronary Artery Stenosis Underwent Percutaneous Coronary Intervention: Comparison of Atorvastatin with Simvastatin/Ezetimibe , 2010, Journal of cardiovascular ultrasound.

[25]  H. Willens,et al.  Echocardiographic epicardial fat: a review of research and clinical applications. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[26]  M. Cotrufo,et al.  Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives. , 2009, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[27]  Udo Hoffmann,et al.  Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. , 2008, European heart journal.

[28]  H. Sasai,et al.  Aerobic exercise training reduces epicardial fat in obese men. , 2009, Journal of applied physiology.

[29]  C. Dieli-Conwright,et al.  Validity and reliability of body composition analysers in children and adults , 2008, British Journal of Nutrition.

[30]  Arya M. Sharma,et al.  Substantial Changes in Epicardial Fat Thickness After Weight Loss in Severely Obese Subjects , 2008, Obesity.

[31]  Udo Hoffmann,et al.  Pericardial Fat, Visceral Abdominal Fat, Cardiovascular Disease Risk Factors, and Vascular Calcification in a Community-Based Sample: The Framingham Heart Study , 2008, Circulation.

[32]  H. Sacks,et al.  Human epicardial adipose tissue: a review. , 2007, American heart journal.

[33]  F. Leonetti,et al.  Epicardial adipose tissue and insulin resistance in obese subjects. , 2005, The Journal of clinical endocrinology and metabolism.

[34]  C. Pond,et al.  Site-specific properties of pericardial and epicardial adipose tissue: the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro. , 1990, International journal of obesity.